Title |
Thalidomide for managing cancer cachexia
|
---|---|
Published in |
Cochrane database of systematic reviews, April 2012
|
DOI | 10.1002/14651858.cd008664.pub2 |
Pubmed ID | |
Authors |
Joanne Reid, Moyra Mills, Marie M Cantwell, Chris R Cardwell, Liam J Murray, Michael Donnelly |
Abstract |
Cancer cachexia is a multidimensional syndrome characterised by wasting, loss of weight, loss of appetite, metabolic alterations, fatigue and reduced performance status. A significant number of patients with advanced cancer develop cachexia before death. There is no identified optimum treatment for cancer cachexia. While the exact mechanism of the action of thalidomide is unclear, it is known to have immunomodulatory and anti-inflammatory properties, which are thought to help reduce the weight loss associated with cachexia. Preliminary studies of thalidomide have demonstrated encouraging results. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 33% |
Scientists | 1 | 33% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | <1% |
Hong Kong | 1 | <1% |
Ireland | 1 | <1% |
Canada | 1 | <1% |
United Kingdom | 1 | <1% |
Unknown | 254 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 41 | 16% |
Researcher | 30 | 12% |
Student > Bachelor | 25 | 10% |
Student > Ph. D. Student | 22 | 8% |
Student > Postgraduate | 16 | 6% |
Other | 50 | 19% |
Unknown | 76 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 91 | 35% |
Nursing and Health Professions | 29 | 11% |
Psychology | 15 | 6% |
Biochemistry, Genetics and Molecular Biology | 9 | 3% |
Social Sciences | 7 | 3% |
Other | 24 | 9% |
Unknown | 85 | 33% |